BofA analyst Joanna Gajuk reinstated coverage of Surgery Partners (SGRY) with a Buy rating and $30 price target from a prior No Rating as the firm no longer believes that the stock is trading “solely on deal speculation.” The firm likes the strong tailwinds for the industry while noting that the stock is trading at a depressed multiple, adding that Ambulatory Surgical Centers should be less exposed to post-election headlines than hospitals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $28 from $38 at JPMorgan
- Surgery Partners price target lowered to $35 from $49 at RBC Capital
- Surgery Partners post-earnings selloff overdone, says Macquarie
- Surgery Partners price target lowered to $31 from $32 at Barclays
- Surgery Partners price target lowered to $34 from $35 at Macquarie